|
 |
|
|||||||
|
|||||||||
Eur Respir J 2008, doi:10.1183/09031936.00129607
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL ARTICLE |
Bronchodilator responsiveness in patients with COPD
1 David Geffen School of Medicine, UCLA, Los Angeles, CA, United States
2 St. Elizabeth's Medical Center, Boston, MA United States
3 University Hospitals, Leuven, Belgium
4 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States
5 Boehringer Ingelheim GmbH, Ingelheim, Germany
* To whom correspondence should be addressed. E-mail: DTashkin{at}mednet.ucla.edu.
 |
Abstract |
|---|
The degree of acute improvement in spirometric indices after bronchodilator inhalation varies among COPD patients and depends on the type, dose and timing of bronchodilator administered.
We examined acute bronchodilator responsiveness at baseline in a large cohort of patients with moderate to very severe COPD participating in UPLIFT, a 4-year, randomized, double-blind trial evaluating the efficacy of tiotropium 18 mcg daily in reducing the rate of decline in lung function. After washout of respiratory medications, patients received 80 mcg ipratropium followed by 400 mcg albuterol. Spirometry was performed before and 90 minutes following ipratropium. Criteria used for FEV1 responsiveness: 
12% and 200 ml, 15% increase over baseline, and 10% absolute increase in percent predicted.
5,756 patients had data meeting criteria for analysis. Age=64.5 years; males=75%. Baseline FEV1=1.10 L (39.3% predicted) and FVC=2.63 L. Compared with baseline, mean improvements in FEV1=229 ml, FVC=407 ml. 53.9% of patients had 12% and 200 ml improvements in FEV1; 65.6% had 15% improvement in FEV1; and 38.6% had 10% absolute increase in FEV1 percent predicted.
The majority of patients with moderate to very severe COPD demonstrate meaningful increases in lung function following administration of an inhaled anticholinergic plus sympathomimetic bronchodilators.
Keywords: Bronchodilator, COPD, reversibility, spirometry, tiotropium
This article has been cited by other articles:
|
|
 |
|
  T. S. Lapperre, J. B. Snoeck-Stroband, M. M.E. Gosman, D. F. Jansen, A. van Schadewijk, H. A. Thiadens, J. M. Vonk, H. M. Boezen, N. H.T. ten Hacken, J. K. Sont, et al. Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease: A Randomized Trial Ann Intern Med, October 20, 2009; 151(8): 517 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Postma and P. Calverley Inhaled corticosteroids in COPD: a case in favour Eur. Respir. J., July 1, 2009; 34(1): 10 - 12. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Dellaca, P. P. Pompilio, P. P. Walker, N. Duffy, A. Pedotti, and P. M. A. Calverley Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD Eur. Respir. J., June 1, 2009; 33(6): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Keaney, A. Kay, and I. Taylor Guidelines and the Diagnosis of COPD Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 734 - 734. [Full Text] [PDF]
|
|
|
|
|
|
J. D Maclay, R. A Rabinovich, and W. MacNee Update in Chronic Obstructive Pulmonary Disease 2008 Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 533 - 541. [Full Text] [PDF]
|
|
|
|
 |
|
 M Hasegawa, H Makita, Y Nasuhara, N Odajima, K Nagai, Y Ito, T Betsuyaku, and M Nishimura Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD Thorax, April 1, 2009; 64(4): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D'Urzo MD MSc Spirometry in primary care practices Can. Med. Assoc. J., February 17, 2009; 180(4): 429 - 430. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, M. Decramer, and the UPLIFT Study Investigators A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease N. Engl. J. Med., October 9, 2008; 359(15): 1543 - 1554. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |